Eicos Sciences

Executive Summary

Eicos Sciences is a private, San Diego-based biotechnology company founded in 2016, dedicated to developing novel prostacyclin (PGI2) analogues for diseases with limited treatment options. Prostacyclins are potent vasodilators with antiplatelet, antiproliferative, and anti-inflammatory properties, making them attractive for cardiovascular, pulmonary, and inflammatory conditions. The experienced team leverages established biology to create differentiated small molecules aimed at improving patient outcomes. Despite being founded nearly a decade ago, the company has disclosed no specific pipeline, partnerships, or funding rounds, suggesting it may be operating in stealth mode or at a very early preclinical stage. The lack of publicly available pipeline data limits visibility into its progress, but the focus on prostacyclin biology—a validated pathway with approved drugs like epoprostenol and treprostinil—provides a credible scientific foundation. The company's potential hinges on advancing novel analogues with improved efficacy, safety, or delivery, though no catalysts can be identified without further disclosure.